Raphaëlle Dequiré-Portier
Gide Loyrette Nouel A.A.R.P.I.Gide Loyrette Nouel A.A.R.P.I. is known for its ‘very good’ knowledge of a broad spectrum of issues, advising a varied client roster of dedicated funds, pharma, and medtech and biotech companies. The group exhibits expertise in a whole host of areas, including distribution and marketing, and dealings with the FCA. Raphaëlle Dequiré-Portier primarily focuses on patent and trade mark disputes in France, and across Europe. IP specialist Emmanuel Larere regularly acts in patent disputes, while Arnaud Duhamel has deep transactional expertise, often advising on securities offerings and privatisations. Promoted to partner in July 2023, Paul Jourdan-Nayrac advises various American and European investment funds, and life sciences growth companies.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Very good knowledge of the subjects and the environment. Expert opinions and advice regarding IP and competition law.’
Key clients
- Imaneo
- Apollo Global Management
- Bristol Myers Squibb
- Bryan, Garnier & Co
- Cathay Innovation
- Dreem SAS
- Elsan
- Gensight Biologics
- Heal Capital
- Inventiva
- Isalt
- LifeSci Capital
- Meril Life Sciences
- Ono Pharmaceutical
- Obvious Ventures
- Orpea
- Phaxiam Therapeutics
- Phoenix Group
- SVB Securities
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
The lawyer(s) leading their teams.
Raphaëlle Dequiré-Portier, Jean-Hyacinthe de Mitry, Emmanuel Larere, Dimitri Dimitrov, Arnaud Duhamel, Anne Tolila